Drug Combination Details
General Information of the Combination (ID: C04341) | |||||
---|---|---|---|---|---|
Name | Elemene NP Info | + | Etoposide Drug Info | ||
Structure |
![]() |
+ |
![]() |
||
Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Synergistic antitumor effect of Beta-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells. |




